About Us

HaliGene is dedicated to advancing transformative gene therapies for ultra-rare neuromuscular and metabolic diseases through a collaborative, science-driven, public-health approach.

Meet our Leaders

Who We Are

About the Company

HaliGene Therapeutics was founded with a singular purpose: to address the unmet needs of ultra-rare disease populations that fall between bespoke academic solutions and commercially tractable pharmaceutical programs. Guided by a public-health lens, we focus on developing scalable platform technologies that enable efficient creation of gene therapies for neuromuscular and metabolic disorders. Our work is driven by scientific rigour, patient partnership, and a commitment to bringing meaningful therapeutic options to communities long overlooked by traditional drug-development models.

At HaliGene, we operate with a lean, collaborative structure designed for capital efficiency and translational impact. Our team works closely with academic researchers, clinicians, and patient groups to accelerate discovery and development while maintaining a science-first approach. Together, we are building a sustainable gene therapy engine capable of delivering innovative treatments, including our lead program, HG-001, a gene replacement therapy for congenital megaconial muscular dystrophy (MDCMC).

Our Impact

Our Promise